LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Association of cannabinoid receptor modulation with normal and abnormal skeletal remodelling: A systematic review and meta-analysis of in vitro, in vivo and human studies.

Photo from wikipedia

To address the inconsistent findings from studies that used different models to explore the role of classical cannabinoid type 1 (CB1) and 2 (CB2) receptors in skeletal remodelling, we searched… Click to show full abstract

To address the inconsistent findings from studies that used different models to explore the role of classical cannabinoid type 1 (CB1) and 2 (CB2) receptors in skeletal remodelling, we searched Medline, Web of Science and Embase for relevant studies from inception to June 23, 2020. We identified 38 in vitro, 34 in vivo and 9 human studies. A meta-analysis of in vitro studies showed that exposure to the inverse-agonists AM251 (mean difference [MD]:-26.75, 95% confidence interval [CI]:-45.36,-8.14, p=0.005), AM630 (standard[std.] MD:-3.11, CI:-5.26,-0.97, p=0.004; SR144528, std.MD:-4.88, CI -7.58,-2.18, p=0.0004) and CBD (std.MD:-1.39, CI -2.64,-0.14, p=0.03) is associated with reduced osteoclastogenesis, whereas the endocannabinoid 2-AG (std.MD:2.00, CI:0.11-3.89, p=0.04) and CB2-selective agonist HU308 (MD:19.38, CI:11.75-27.01, p<0.00001) were inhibitory. HU308 also enhanced osteoblast differentiation (std.MD:2.22, CI:0.95-3.50, p=0.0006) and activity (std.MD:2.97, CI:1.22-4.71, p=0.0008). In models of bone loss, CB1/2 deficiency enhanced peak bone volume (std.MD:3.70, CI:1.77-5.63, p=0.0002) and bone formation (std.MD:-0.54, CI:-0.90,-0.17, p=0.004) in female mice. In male rats, CB1/2 deficiency (std.MD:2.31, CI:0.30-4.33, p=0.02) and AM251 or CBD treatments (std.MD:2.19, CI:0.46-3.93, p=0.01) enhanced bone volume. CB1/2 deficiency (std.MD:9.78, CI:4.96-14.61, p<0.0001) and AM251 or AM630 treatments (std.MD:28.19, CI:19.13-37.25, p<0.0001) were associated with osteoprotection. The CB2-selective agonists JWH133 and 4Q3C enhanced bone volume in arthritic rodents (std.MD:14.45, CI:2.08-26.81, p=0.02). In human, CB2 SNPs (AA:rs2501431, MD:-0.28, CI:-0.55,-0.01, p=0.04; CC:rs2501432, MD:-0.29, CI:-0.56,-0.02, p=0.03) were associated with reduced bone mineral density, however the association of Marijuana use remains unclear. Thus, CB1/2 modulation is associated with altered bone metabolism, however findings are confounded by low study number and heterogenicity of models. DATA AVAILABILITY: The datasets used and analysed in the present study are available from the public sources described.

Keywords: skeletal remodelling; vitro vivo; bone; human studies; vivo human; std

Journal Title: Pharmacological research
Year Published: 2021

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.